Literature DB >> 17507983

Herpesvirus latency confers symbiotic protection from bacterial infection.

Erik S Barton1, Douglas W White, Jason S Cathelyn, Kelly A Brett-McClellan, Michael Engle, Michael S Diamond, Virginia L Miller, Herbert W Virgin.   

Abstract

All humans become infected with multiple herpesviruses during childhood. After clearance of acute infection, herpesviruses enter a dormant state known as latency. Latency persists for the life of the host and is presumed to be parasitic, as it leaves the individual at risk for subsequent viral reactivation and disease. Here we show that herpesvirus latency also confers a surprising benefit to the host. Mice latently infected with either murine gammaherpesvirus 68 or murine cytomegalovirus, which are genetically highly similar to the human pathogens Epstein-Barr virus and human cytomegalovirus, respectively, are resistant to infection with the bacterial pathogens Listeria monocytogenes and Yersinia pestis. Latency-induced protection is not antigen specific but involves prolonged production of the antiviral cytokine interferon-gamma and systemic activation of macrophages. Latency thereby upregulates the basal activation state of innate immunity against subsequent infections. We speculate that herpesvirus latency may also sculpt the immune response to self and environmental antigens through establishment of a polarized cytokine environment. Thus, whereas the immune evasion capabilities and lifelong persistence of herpesviruses are commonly viewed as solely pathogenic, our data suggest that latency is a symbiotic relationship with immune benefits for the host.

Entities:  

Mesh:

Year:  2007        PMID: 17507983     DOI: 10.1038/nature05762

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  332 in total

Review 1.  Immune modulation during latent herpesvirus infection.

Authors:  Douglas W White; R Suzanne Beard; Erik S Barton
Journal:  Immunol Rev       Date:  2012-01       Impact factor: 12.988

Review 2.  Control of antiviral immunity by pattern recognition and the microbiome.

Authors:  Iris K Pang; Akiko Iwasaki
Journal:  Immunol Rev       Date:  2012-01       Impact factor: 12.988

Review 3.  Heterologous immunity between viruses.

Authors:  Raymond M Welsh; Jenny W Che; Michael A Brehm; Liisa K Selin
Journal:  Immunol Rev       Date:  2010-05       Impact factor: 12.988

4.  Sleep and fatigue in mice infected with murine gammaherpesvirus 68.

Authors:  Melissa D Olivadoti; Jason B Weinberg; Linda A Toth; Mark R Opp
Journal:  Brain Behav Immun       Date:  2011-01-24       Impact factor: 7.217

5.  Metagenomics and personalized medicine.

Authors:  Herbert W Virgin; John A Todd
Journal:  Cell       Date:  2011-09-30       Impact factor: 41.582

6.  Parasite and host assemblages: embracing the reality will improve our knowledge of parasite transmission and virulence.

Authors:  Thierry Rigaud; Marie-Jeanne Perrot-Minnot; Mark J F Brown
Journal:  Proc Biol Sci       Date:  2010-07-28       Impact factor: 5.349

7.  Composite Agency: Semiotics of Modularity and Guiding Interactions.

Authors:  Alexei A Sharov
Journal:  Biosemiotics       Date:  2017-07-27       Impact factor: 0.711

8.  LXR Alpha Restricts Gammaherpesvirus Reactivation from Latently Infected Peritoneal Cells.

Authors:  P T Lange; C N Jondle; E J Darrah; K E Johnson; V L Tarakanova
Journal:  J Virol       Date:  2019-03-05       Impact factor: 5.103

9.  Development of a high-throughput assay to measure the neutralization capability of anti-cytomegalovirus antibodies.

Authors:  Thomas J Gardner; Cynthia Bolovan-Fritts; Melissa W Teng; Veronika Redmann; Thomas A Kraus; Rhoda Sperling; Thomas Moran; William Britt; Leor S Weinberger; Domenico Tortorella
Journal:  Clin Vaccine Immunol       Date:  2013-02-06

Review 10.  'From immunosenescence to immune modulation': a re-appraisal of the role of cytomegalovirus as major regulator of human immune function.

Authors:  Paul Moss
Journal:  Med Microbiol Immunol       Date:  2019-05-03       Impact factor: 3.402

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.